Agri Investment Fund

Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.

Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.

Animab is a biotechnology company specializing in proprietary technology that supports livestock health. Animab combines cutting-edge research, animal science, and biotechnology to create products that improve animal health, reduce costs, and are more sustainable. Animab provides a safe and long-term solution for protecting piglets' intestinal health during the critical post-weaning stage. The antibodies in Animab are designed to mimic secretory IgA, a type of natural antibody that is passed through colostrum and milk to protect nursing animals.

ViroVet is an innovative company focused on developing groundbreaking technologies to combat viral diseases in livestock, particularly through antiviral drugs targeting respiratory disease complexes and novel vaccines for swine. The livestock industry, valued at over 100 billion euros, faces significant financial losses due to viral diseases, which threaten global animal protein supplies. ViroVet aims to supply livestock producers, national governments, and international organizations with comprehensive solutions that can be used independently or alongside existing vaccines and biosecurity measures. With the growing world population and increased demand for protein, the risk of viral disease spread in densely populated livestock environments is rising. ViroVet has garnered support from key opinion leaders in livestock medicine, who recognize the potential of its products to reduce antibiotic use and transform the industry. Through its innovative approach, ViroVet addresses urgent challenges posed by endemic and epizootic viral diseases, ultimately aiming to enhance the resilience of the livestock sector.

Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.

Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.

Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics for pets and livestock. It operates a proprietary platform dedicated to creating innovative treatments for significant viral diseases, with five candidates currently in clinical or development stages. The company specializes in addressing viral infections affecting pets, particularly through its work on feline herpes and feline immunodeficiency virus. Okapi Sciences is committed to advancing its pipeline of antiviral drugs while fostering strong relationships with academic institutions to enhance its research capabilities and technological advancements in veterinary medicine.

Fugeia NV is develops ingredients and nutrition technologies. The company offers arabinoxylan-oligosaccharides (AXOS) ingredient that provides the health benefits of wholegrain wheat as part of the human diet, particularly in the prevention of lifestyle diseases, such as diabetes, obesity, cardiovascular diseases, and cancer; Prebiotic bread technology that allows to increase the level of arabinoxylan-oligosaccharides in bread; and AXOS-enriched beer technology that allows to increase the level of arabinoxylan-oligosaccharides. It develops products and technologies targeted for a range of market segments, including dairy and non-dairy beverages, ready-to-eat cereals, cookies and biscuits, and bread and pastry, as well as dietary supplements and therapeutics.